Skip to content

Effect and mechanism of ulinastatin in joint replacement

Effect of using ulinastatin perioperative on reduction of opioid consumption and near-term quality of life after hip replacement - Effect and mechanism of ulinastatin in joint replacement

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072126
Enrollment
Unknown
Registered
2023-06-03
Start date
2023-05-31
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative pain

Interventions

UTI group:100,000 units of ulinastatin were continuously pumped during the operation, and the postoperative analgesic pump was Apon electronic analgesic pump ZZB-?150ml. 500,000 units of ulinastatin,
NS group: the postoperative analgesic pump was Apon electronic analgesic pump ZZB-?150ml,2mg of haloperidol, 37.5mg of dolastron and 120mg of morphine were added into the pump. The first dose of 5ml w

Sponsors

Tianjin Jizhou District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Hip/knee replacement patients aged 40-80 years ,40-80kg,due to trauma or fracture and diagnosed with OA 2. Awake, able to understand NRS and BPI scores, and able to complete the BPI patient Assessment manual 3. Patients who signed written informed consent for the study 4.ASA is from ? to ?

Exclusion criteria

Exclusion criteria: (1) Using or the doctor think you need to use the surprised resistance, or antidepressant drugs neuropathy pain patients (such as tumor compression nerve trunk, nerve plexus and spinal cord). Analgesics other than study drugs, including NSAIDs, are being used or are considered necessary by a physician; 2. There are unstable accompanying diseases; Or patients with dysfunction of vital organs; 3. Patients with a known allergy to opioids; 4. Patients who may change their drug combinations (other than those treating adverse reactions to opioids) during the study period; 5. According to the judgment of the researcher, patients who are not suitable to participate in this study for any reasons other than inclusion criteria and exclusion criteria, including patients who do not have full capacity for civil conduct

Design outcomes

Primary

MeasureTime frame
consumption of Morphine ;

Secondary

MeasureTime frame
inflammatory factors;

Countries

China

Contacts

Public ContactLIUYING

Tianjin Jizhou District People's Hospital

2088954151@qq.com+86 22 6073 3505

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026